Prior Art Litigation Search in Melbourne.

A prior art search Melbourne litigation counsel can rely on has to match where the fights actually start — and in Victoria’s capital that means life sciences, medical devices and advanced manufacturing. Melbourne anchors Australia’s densest biomedical cluster, the Parkville precinct, where CSL runs its global headquarters and research centre alongside WEHI, the University of Melbourne, the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. When those portfolios are asserted, validity and infringement are decided together in a single trial before the Federal Court of Australia, sitting in Melbourne but exercising a national jurisdiction. PerspireIP builds invalidity-grade searches for the parties challenging those patents, scoped to revocation under the Patents Act 1990. Send us the patent number and we will get started.

Where a prior art search Melbourne case is actually heard

Australian patent litigation is not spread across state courts. Infringement and validity are heard by the Federal Court of Australia, which exercises a single national jurisdiction over the Patents Act 1990. The court runs an Intellectual Property National Practice Area, and within it a specialist Patents and Associated Statutes sub-area, so a Melbourne matter is docketed to a judge experienced in patent work. First-instance cases are heard by a single judge — there are no jury trials for patents in Australia.

The point that shapes how prior art is used is that Australia does not bifurcate validity from infringement. Unlike the German model, there is no separate court or office that rules on validity while another rules on infringement. Both are tried together in one liability hearing, so an accused party’s invalidity attack has to be trial-ready from the outset rather than parked for a later forum. What the Federal Court commonly does split off is quantum — liability is decided first, and if infringement stands, the account of profits or damages inquiry follows as a separate stage.

Because Melbourne sits within a national court, an accused party is not tied to a local registry. A proceeding can be commenced in the Victoria District Registry and managed there, but the Federal Court’s docket system and national practice mean the law applied is uniform across the country. Appeals run to the Full Court of the Federal Court, and from there, only by special leave, to the High Court of Australia.

• Federal Court of Australia, IP National Practice Area — the Patents and Associated Statutes sub-area hears infringement and revocation nationally
• Single judge, no jury — first-instance patent trials are decided by one specialist judge
• No validity/infringement bifurcation — both are tried together, so invalidity art must be ready from day one
• Full Court then the High Court — appeals go to the Full Court of the Federal Court, and to the High Court only on special leave

Revocation grounds under the Patents Act 1990

In Australia a patent is knocked out through revocation, and the grounds sit in section 138 of the Patents Act 1990. Any person may apply to the Federal Court to revoke a patent, and an accused infringer almost always runs invalidity as a cross-claim inside the infringement suit — which, because the court does not bifurcate, is decided in the same proceeding. Section 138(3) lists the grounds the court can act on.

The grounds that turn on prior art run through the definition of a patentable invention in section 18. An invention must be novel and involve an inventive step when compared with the prior art base as it stood before the claim’s priority date. A single earlier disclosure that contains every integer of the claim destroys novelty; a claim that is obvious to the skilled person, often over a combination of references read with the common general knowledge, fails for want of inventive step. Alongside these sit entitlement, non-compliance with the specification requirements of section 40, and patents obtained by false suggestion or misrepresentation.

• Not novel — a single prior disclosure anticipates every integer of the claim
• No inventive step — the claim is obvious over the prior art and common general knowledge
• Section 40 non-compliance — the specification fails to disclose the invention clearly and completely, or the claims are not supported
• Not entitled / false suggestion — the patentee was not entitled, or the patent was obtained by misrepresentation

Novelty and inventive step are where an invalidity search earns its keep, because the strength of the art — how tightly it maps to the claimed integers and how firmly its public-availability date is proved — often decides the case well before final submissions.

Raising the Bar: why older patents are now easier to attack

The single most important thing to know before challenging an Australian patent is which law governs it. The Intellectual Property Laws Amendment (Raising the Bar) Act 2012 commenced on 15 April 2013 and lifted the validity thresholds substantially, so the test that applies depends on the patent’s examination timeline. For an accused party, the reformed standards are friendlier ground — they make obviousness and insufficiency attacks materially stronger.

On inventive step, Raising the Bar made two changes that widen the pool of usable prior art. It removed the old geographical limitation on common general knowledge, so knowledge held anywhere in the world — not just in Australia — now counts against the patentee. And it scrapped the requirement that a prior art document be one the skilled person could be expected to have ascertained, understood and regarded as relevant. That gate previously excluded obscure references; after the reform, a much broader body of publications can be combined to show a claim was obvious.

The reforms also tightened section 40. The specification must now enable the skilled person to perform the invention across the full width of the claims, and the claims must be supported by the disclosure rather than merely “fairly based” on it — standards deliberately aligned with the UK and the EPO. For an invalidity search this matters twice over: it widens what prior art can be deployed on obviousness, and it opens a disclosure-based line of attack that a good search can help substantiate by showing what the specification actually taught at the priority date.

The end of the innovation patent, and what it means for accused parties

Australia used to offer a second-tier right, the innovation patent, which was granted quickly, ran for eight years and required only an innovative step — a lower bar than the inventive step demanded of a standard patent. It was a favourite weapon for fast, aggressive enforcement, and accused parties often faced a swiftly certified innovation patent carved out of a pending application.

That door is now closing. IP Australia stopped accepting new innovation patent applications filed on or after 26 August 2021. The system is being phased out: innovation patents already filed on or before 25 August 2021 remain in force until they expire, and in limited cases a divisional off an earlier-filed application can still reach back into the system. But no genuinely new innovation patent can be created, and the pool is shrinking year on year, leaving the standard patent as the only forward route.

For a party sued in Melbourne, this changes the invalidity calculus. Any lingering innovation patent still turns on the low innovative-step threshold, which shapes how prior art is argued against it, while every newly asserted right will be a standard patent measured against the full, Raising-the-Bar inventive-step test. Knowing which regime and which threshold governs the patent in front of you is the first thing we pin down, because it dictates the depth and reach the prior art search has to achieve.

Biotech and life sciences: Melbourne’s prior art frontier

Melbourne is the heart of Australian life sciences. The Parkville biomedical precinct brings together CSL, which relocated its global headquarters and research and development centre there, the Walter and Eliza Hall Institute (WEHI), the University of Melbourne, the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre, with the Jumar Bioincubator seeding a pipeline of biotech start-ups. When these portfolios — therapeutics, antibodies, plasma products, diagnostics and platform technologies — are asserted, the accused party needs an invalidity case built for the toughest evidentiary terrain in patent law.

Life-sciences validity fights are won and lost on non-patent literature. The decisive reference is rarely a prior patent; it is a journal article, a conference abstract, a clinical-trial registration, a thesis or a database deposit. Sequence disclosures in public repositories, protein and gene database records, and dated clinical-trial protocols frequently anticipate a claim or render it obvious — but only if their public-availability date can be proved to the day. Establishing exactly when a poster was displayed or when a database entry became accessible is often the hardest-fought issue in the case.

A prior art search Melbourne biotech defendants can build a revocation case on has to reach into all of that grey literature, in multiple languages, and chart each reference against the claimed integers. Because Raising the Bar removed the geographical and “ascertainment” limits on what can be cited, a foreign conference paper or an overseas laboratory’s dated protocol is now fully in play — and that is exactly the material we retrieve and date for a life-sciences invalidity search.

Biopharmaceutical claims also raise their own disclosure questions under section 40. A therapeutic or antibody claim drawn broadly must be enabled across its full width and supported by the specification, so a search that documents what was actually known and taught at the priority date can underpin an insufficiency or lack-of-support attack as well as the obviousness case. We build the record with both lines in mind, so a single body of dated art serves the whole revocation cross-claim.

Medical devices, manufacturing and agritech

Beyond therapeutics, Victoria carries a deep medical-device and advanced-manufacturing base, from implantable and surgical technologies developed around the hospital precincts to precision engineering and additive manufacturing across the state’s industrial suburbs. Device patents blend mechanical, electronic and software integers, and when they are asserted the accused maker has to show the claimed combination was already known — work that reaches into engineering standards, regulatory filings, product manuals, trade-show disclosures and older device documentation that never surfaced during examination.

Victoria is also a national leader in agritech and agricultural science, spanning crop genetics, animal health, sensing and farm-automation technologies. That subject-matter throws up its own invalidity sources — agronomy journals, government and CSIRO-linked research reports, field-trial records, breeders’ rights material and equipment manuals — where public availability again turns on careful dating rather than a tidy patent citation.

Across all of these fields the pattern holds: the reference that decides a Melbourne case is usually the one the original examiner never saw. Our job is to find it, date it and chart it, so that in a single unbifurcated Federal Court trial the invalidity case stands up alongside the non-infringement arguments rather than trailing behind them. Because liability is decided in one hearing, the art has to be marshalled and evidenced before trial rather than staged for a later validity forum that, in Australia, does not exist.

How PerspireIP builds a Melbourne invalidity search

Every engagement follows the same disciplined path. We map the asserted claims integer by integer, fix the priority date that actually governs each claim, and search against that date rather than the filing date printed on the cover. We confirm which legal regime applies — pre- or post-Raising-the-Bar, standard patent or a surviving innovation patent — because that sets the inventive-step and disclosure thresholds the art has to clear.

• Claim charting mapped to novelty and inventive step under sections 18 and 138 of the Patents Act 1990
• Deep non-patent retrieval — journals, conference material, clinical-trial registrations, sequence and gene databases, standards, theses and product literature
• Public-availability dating for every reference, evidenced to the day for posters, database records and online disclosures alike
• Regime-aware scoping that accounts for the Raising the Bar thresholds and any surviving innovation-patent right
• A written invalidity analysis and reference packages ready for a Federal Court revocation cross-claim or a pre-suit assessment

We work alongside your Australian patent attorneys and litigation counsel as a specialist search partner, deliver to Federal Court timetables, and keep every engagement confidential. Whether you are a device maker facing an assertion, a biotech challenging a competitor’s therapeutic claim, or litigation counsel preparing a revocation defence, we scale to fit — a single search, a multi-patent campaign or ongoing portfolio support. Send us the patent number and your key dates, and we will scope a prior art search Melbourne project within one business day.

IP Landscape & Resources in Melbourne

Key intellectual-property authorities and venues relevant to Melbourne:

• IP Australia — the Australian government agency that grants standard patents and administers the closed innovation-patent system
• Federal Court of Australia — hears patent infringement and revocation nationally through its Intellectual Property National Practice Area, with validity and infringement tried together
• Patents Act 1990 (Federal Register of Legislation) — the governing statute, whose sections 18 and 138 set the novelty, inventive-step and revocation standards as amended by the Raising the Bar Act 2012
• WIPO Lex — Australia — WIPO's record of the Patents Act 1990 and related Australian IP legislation

Request a Prior Art Search in Melbourne

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions